Truist on Tourmaline Bio (TRML): 'CV Represents Significant Potential Upside Not Reflected at CMP'
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $74.00 price target on Tourmaline Bio (NASDAQ: TRML).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
